# Astrabio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/astrabio

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.astra-biotech.com
- Total disclosed funding: $22M
- Latest round: Series B (Sep 1, 2026)
- Investors on record: 5

## About

Based in Jiangsu, China, and founded in 2019, Suzhou ASTRABIO Co., Ltd., trading as Astrabio, operates as a diagnostic equipment developer that focuses on single-molecule immunodiagnostic technology. The company also established an 8000-square meter of research and development and production centre. It has applied for more than 40 patents and has passed ISO 13485:2016 Medical Device Quality Management System Certification. In November 2022, the fully automated single molecule immunoassay analyzer developed by the company has entered into the application process for registration of innovative products for medical devices. In September 2026, Astrabio raised over CNY 50 million in Series B funding led by Taizhou Zhanxin Private Equity Fund Management Co., Ltd., with participation from Univ Biotechnology and LH Ventures.

The company primarily engages in the research, development, production, and sales of next-generation immunodiagnostic equipment and reagents. Its main products include the AST-Sc-Ulti ultrasensitive single-molecule immunoassay analyzer and the AST-Dx90 single-molecule immunodiagnostic analyzer.

The company generates revenue by developing, manufacturing, and selling immunodiagnostic instruments, diagnostic reagents, and related testing solutions and services.

The Series B funding raised in September 2026 will be used to accelerate Astrabio's ecosystem construction across the entire lifecycle of neurological diseases: Domestically, the company is deepening its layout in the field of Alzheimer's disease and gradually expanding to more brain-related diseases such as Parkinson's disease and stroke, covering application scenarios such as medical diagnosis, health checkups, and scientific research. Simultaneously, the company is accelerating the construction of its global commercialization network and overseas product registration, enhancing the international market competitiveness of domestically produced neurodiagnostic products, and steadily promoting the globalization of Chinese neurodiagnostic brands.

## Funding rounds

- Series B, Sep 1, 2026, $7.4M — Univ Biotechnology, LH Ventures
- Series A, Jun 29, 2022, $15M — Shanghai Jianyi Private Equity Fund Management, Puhua Capital, BioTrack Capital

## Investors

- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series A
- Puhua Capital (https://capitalatlas.ai/funds/puhua-capital) — Series A
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series A
- Univ Biotechnology — Series B
- LH Ventures (https://capitalatlas.ai/funds/lh-ventures) — Series B